Arquimea has incorporated its first promissory note and bond programs in the Mercado Alternativo de Renta Fija (MARF) for a maximum amount of 75 and 100 million euros, respectively. Over the next 12 months, the promissory note program will enable it to issue notes with a maturity of between 3 days and two years, while the bond program will enable it to issue medium and long-term debt.
Arquimea is a multi-sector technology company that operates globally in different sectors of the economy. The company was founded in 2005 and today has a workforce of more than 500 professionals in its five main areas of activity: Aerospace, Fintech, Agrotech, Healthcare and Industrial Services. Arquimea's main value is its capacity for Research, Development and Innovation (R&D&I), with science being the engine of development that allows it to solve specific problems of society through technology and innovative solutions, for which it has a corporate research center called Arquimea Research Center.
Arquimea stands out, thanks to its more than 15 years of experience, in the fields of electronics, microelectronics, mechanics, aeronautics, software, artificial intelligence and technologies for genetic analysis, among others. Currently, the company has diversified its business both through the generation of its own technologies and through the integration of other companies that share the same objectives and vision. Arquimea is one of the leaders in technological sponsorship in Spain and in the last 5 years has contributed to promote more than 150 projects and at the end of 2021 it expects to mobilize a total volume of more than 320 million euros in R&D&I.
PKF Attest and Beka Finance act as Placement Entities in the note program, with PKF Attest acting as Registered Advisor in the note program. In the bond program, PKF Attest is both Placement Entity and Registered Advisor. J&A Garrigues has been the legal advisor for both transactions.
The company obtained a long-term rating of BB with a stable trend from Axesor Rating.
At the close of its last fiscal year, in March 2021, ARQUIMEA Group had a turnover of 72 million euros and an adjusted EBITDA of 15.3 million euros.
_________________________________________________________________________________________
Commercial Papers are an efficient source of funding
Commercial Papers are short-term money-market securities used as a funding source by financial institutions, as well as governments, supranational agencies and mid and large corporations.
For corporate issuers, Commercial Papers are an extremely efficient funding source, that is complementary to banking facilities and credit lines. It is an efficient working capital solution via Debt Capital Markets.
Commercial Papers are issued under a shelf programme with a predetermined maximum outstanding size, and that are renewable annually (or every 3 years for STEP label). CPs may be issued at a discount or at a premium, they may bear fixed or floating rate interest, although they most usually carry an implicit coupon.
Maturity of Notes ranges from 1 to 364 days for ECP (European Commercial Paper Programmes), up to 24 months for Spanish Pagarés and up to 36 months for Italian Cambiali Finanziarie.
Commercial Papers are multi-currency instruments that can be issued in different currencies, predominantly in EUR, USD, CHF and GBP. They have a minimum denomination of €100K and are intended for wholesale institutional investors, both national and international.
Commercial Papers are issued under a shelf programme with a predetermined maximum outstanding size, and that are renewable annually (or every 3 years for STEP label). CPs may be issued at a discount or at a premium, they may bear fixed or floating rate interest, although they most usually carry an implicit coupon.
Maturity of Notes ranges from 3 days to 24 months for Pagarés Programmes and from 1 to 364 days for ECP (European Commercial Paper Programmes).
Commercial Papers are multi-currency instruments that can be issued in different currencies, predominantly in EUR, USD, CHF and GBP. They have a minimum denomination of €100K and are intended for wholesale institutional investors, both national and international.
Source: BME(Read the complete article)
